Clinical trial
Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease
NCT00462189 · Cambridge Antibody Technology, Other · Unknown status
Key facts
| NCT number | NCT00462189 |
|---|---|
| Title | Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease |
| Official title | A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patient With Relapsed or Refractory Hairy Cell Leukemia (HCL) |
| Lead sponsor | Cambridge Antibody Technology, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia, Hairy Cell Leukemia, HCL |
| Intervention type | Drug, Procedure |
| Interventions | Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy |
| Enrollment | 40 |
| Start date | Apr 1, 2007 |
| First posted | Apr 18, 2007 |
| Last update posted | Apr 18, 2007 |
| Countries | Poland, United Kingdom, United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: